Celldex Therapeutics Ownership

CLDX Stock  USD 25.60  1.41  5.22%   
The majority of Celldex Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Celldex Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Celldex Therapeutics. Please pay attention to any change in the institutional holdings of Celldex Therapeutics as this could imply that something significant has changed or is about to change at the company.
Some institutional investors establish a significant position in stocks such as Celldex Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Celldex Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates.
For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.

Celldex Stock Ownership Analysis

About 100.0% of the company shares are held by institutions such as insurance companies. The book value of Celldex Therapeutics was currently reported as 9.01. The company recorded a loss per share of 3.38. Celldex Therapeutics last dividend was issued on the 11th of February 2019. The entity had 1:15 split on the 11th of February 2019. Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey. Celldex Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 132 people. For more info on Celldex Therapeutics please contact the company at 908 200 7500 or go to https://www.celldex.com.

Celldex Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Celldex Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Celldex Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Celldex Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Ronald Pepin over two weeks ago
Disposition of 11000 shares by Ronald Pepin of Celldex Therapeutics at 2.78 subject to Rule 16b-3
 
Richard Wright over three months ago
Acquisition by Richard Wright of 28469 shares of Celldex Therapeutics at 28.0 subject to Rule 16b-3
 
Marucci Anthony S over three months ago
Acquisition by Marucci Anthony S of 11500 shares of Celldex Therapeutics at 26.82 subject to Rule 16b-3
 
Heath-chiozzi Margo over three months ago
Acquisition by Heath-chiozzi Margo of 2608 shares of Celldex Therapeutics at 10.38 subject to Rule 16b-3
 
Heath-chiozzi Margo over six months ago
Disposition of 29068 shares by Heath-chiozzi Margo of Celldex Therapeutics at 2.78 subject to Rule 16b-3
 
Elizabeth Crowley over six months ago
Acquisition by Elizabeth Crowley of 85000 shares of Celldex Therapeutics at 36.43 subject to Rule 16b-3
 
Marino James J over a year ago
Disposition of 10500 shares by Marino James J of Celldex Therapeutics subject to Rule 16b-3
 
Marucci Anthony S over a year ago
Acquisition by Marucci Anthony S of 11500 shares of Celldex Therapeutics at 26.82 subject to Rule 16b-3
 
Heath-chiozzi Margo over a year ago
Acquisition by Heath-chiozzi Margo of 2043 shares of Celldex Therapeutics at 9.0165 subject to Rule 16b-3
 
Wright Richard M. over a year ago
Disposition of 18375 shares by Wright Richard M. of Celldex Therapeutics at 22.48 subject to Rule 16b-3
 
Penner Harry Jr over a year ago
Acquisition by Penner Harry Jr of 16500 shares of Celldex Therapeutics at 36.43 subject to Rule 16b-3
 
Elizabeth Crowley over a year ago
Disposition of 34445 shares by Elizabeth Crowley of Celldex Therapeutics at 2.78 subject to Rule 16b-3

Celldex Therapeutics Outstanding Bonds

Celldex Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Celldex Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Celldex bonds can be classified according to their maturity, which is the date when Celldex Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.